EU/3/18/2087
Table of contents
About
On 19 November 2018, orphan designation (EU/3/18/2087) was granted by the European Commission to Consejo Superior de Investigaciones Cientificas, Spain, for etamsylate for the treatment of hereditary haemorrhagic telangiectasia.
The sponsorship was transferred to Dobecure S.L., Spain in June 2020.
Key facts
Active substance |
Etamsylate
|
Disease / condition |
Treatment of hereditary haemorrhagic telangiectasia
|
Date of first decision |
19/11/2018
|
Outcome |
Positive
|
EU designation number |
EU/3/18/2087
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
Dobecure S.L.
Calle De San Emilio 6 Local 1
28017 Madrid
Spain
Tel: +34 691 494 049
E-mail: alfonso.garcia@dobecure.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.